Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (GB:0EE0)
LSE:0EE0
uniQure (0EE0) Share Price & Analysis
1 Followers
0EE0 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.29 - $22.20
Previous Close$4.41
Volume110.00
Average Volume (3M)1.77K
Market Cap
$221.82M
Enterprise Value$118.87M
Total Cash (Recent Filing)$241.36M
Total Debt (Recent Filing)$138.41M
Price to Earnings (P/E)N/A
Beta1.25
Next Earnings
Jul 31, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding47,838,275
10 Day Avg. Volume215
30 Day Avg. Volume1,766
Standard Deviation0.23
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)1.81
Price to Sales (P/S)110.89
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.30
Enterprise Value/Gross Profit7.53
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$18.86Price Target Upside314.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
uniQure News
Bulls Say, Bears Say
Bulls Say
Financial HealthThe company has a substantial cash reserve, with cash, cash equivalents, and marketable securities expected to fund operations well into the future.
Product Pipeline DevelopmentUniQure expects to provide an interim update from the ongoing Phase 1/2 trials which may support a collaboration ahead of a potential pivotal program.
Regulatory MilestonesInitial FDA discussions for AMT-130 are projected, which may clarify the pathway for its potential approval and commercialization.
Bears Say
Clinical Data ConcernsData observed to date for AMT-130 has been difficult to interpret, including a lack of clear dose response.
Partnership RisksVisibility on timing to a partnership for AMT-130 is unclear, adding risks to the investment thesis.
Regulatory ChallengesAnalyst downgrades QURE stock due to uncertainty on the future development/regulatory path of AMT-130 in Huntington's disease.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.48% Other Institutional Investors
97.52% Public Companies and
Individual Investors
0EE0 FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest share price was $4.29 and its highest was $22.20 in the past 12 months.
What is uniQure N.V.’s market cap?
Currently, no data Available
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Jul 31, 2024 which is in 89 days.
How were uniQure N.V.’s earnings last quarter?
Currently, no data Available
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does uniQure N.V. have?
Currently, no data Available
What happened to uniQure N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of uniQure N.V.?
Among the largest hedge funds holding uniQure N.V.’s share is Bridger Management, LLC. It holds uniQure N.V.’s shares valued at 2M.
---
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.86 (314.51% Upside)
$18.86 (314.51% Upside)
Blogger Sentiment
Bullish
GB:0EE0 Sentiment 80%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $339.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.79%
12-Months-Change
Fundamentals
Return on Equity
-90.24%
Trailing 12-Months
Asset Growth
17.98%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
---
0EE0 Stock 12 Months Forecast
Average Price Target
$18.86
▲(314.51% Upside)
Technical Analysis
Best Analysts Covering 0EE0
1 Year
1 Year Success Rate
17/40 ratings generated profit
1 Year Average Return
+6.13%
reiterated a buy rating 11 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 42.50% of your transactions generating a profit, with an average return of +6.13% per trade.
---